Skip to main content

ARGX

Stock
Health Care
Biotechnology

Performance overview

ARGX Price
Price Chart

Forward-looking statistics

Beta
0.68
Risk
32.53%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Company info

SectorHealth Care
IndustryBiotechnology
Employees742
Market cap$22.3B

Fundamentals

Enterprise value$30.3B
Revenue$2.6B
Revenue per employee—
Profit margin40.26%
Debt to equity0.71

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)$16.41
Dividend per share—
Revenue per share$1.75
Avg trading volume (30 day)$200M
Avg trading volume (10 day)$281M
Put-call ratio—

Macro factor sensitivity

Growth+2.8
Credit+17.8
Liquidity-5.7
Inflation-1.8
Commodities+0.4
Interest Rates-1.7

Valuation

Dividend yield0.00%
PEG Ratio56.09
Price to sales12.56
P/E Ratio56.09
Enterprise Value to Revenue11.46
Price to book6.01

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

EXEL or ARGX: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research (July 3, 2025)
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Argenx SE ARGX stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase).

Benzinga (June 30, 2025)
Biotech stocks: Which drugmakers are worth a buy?

While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation biotech stocks could offer. But with so many names and new research coming out every day, it can be difficult to find where to start.

Yahoo Finance (August 12, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free